JPS60501859A - 酵素誘導体 - Google Patents

酵素誘導体

Info

Publication number
JPS60501859A
JPS60501859A JP59502568A JP50256884A JPS60501859A JP S60501859 A JPS60501859 A JP S60501859A JP 59502568 A JP59502568 A JP 59502568A JP 50256884 A JP50256884 A JP 50256884A JP S60501859 A JPS60501859 A JP S60501859A
Authority
JP
Japan
Prior art keywords
protein
group
enzyme
derivative according
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59502568A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0567278B2 (enExample
Inventor
スミス，リチヤード　アンソニー　ゴドウイン
キヤツセルス　ロバート
Original Assignee
ビ−チヤム　グル−プ　ピ−．エル．シ−．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビ−チヤム　グル−プ　ピ−．エル．シ−． filed Critical ビ−チヤム　グル−プ　ピ−．エル．シ−．
Publication of JPS60501859A publication Critical patent/JPS60501859A/ja
Publication of JPH0567278B2 publication Critical patent/JPH0567278B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP59502568A 1983-07-20 1984-07-04 酵素誘導体 Granted JPS60501859A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB838319538A GB8319538D0 (en) 1983-07-20 1983-07-20 Compounds
GB8319538 1983-07-20

Publications (2)

Publication Number Publication Date
JPS60501859A true JPS60501859A (ja) 1985-10-31
JPH0567278B2 JPH0567278B2 (enExample) 1993-09-24

Family

ID=10545987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59502568A Granted JPS60501859A (ja) 1983-07-20 1984-07-04 酵素誘導体

Country Status (6)

Country Link
US (1) US4604285A (enExample)
EP (1) EP0151593B1 (enExample)
JP (1) JPS60501859A (enExample)
DE (1) DE3476785D1 (enExample)
GB (1) GB8319538D0 (enExample)
WO (1) WO1985000521A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238536A (ja) * 1987-11-17 1989-09-22 Scripps Clinic Res Found 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物
JPH05170666A (ja) * 1991-06-20 1993-07-09 Immuno Ag プロテインｃを含有し血栓溶解活性を有する非経口投与が可能な薬剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
FR2658517B2 (fr) * 1989-04-12 1992-06-19 Fondation Nale Transfusion San Preparation de la proteine c activee et solution de proteine c activee ainsi obtenue.
FR2645865B1 (fr) * 1989-04-12 1991-07-12 Fondation Nale Transfusion San Procede de preparation de la proteine c activee et solution de proteine c activee ainsi obtenue
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US20040072757A1 (en) * 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
EP0091240B1 (en) * 1982-04-07 1985-12-27 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238536A (ja) * 1987-11-17 1989-09-22 Scripps Clinic Res Found 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物
JPH05170666A (ja) * 1991-06-20 1993-07-09 Immuno Ag プロテインｃを含有し血栓溶解活性を有する非経口投与が可能な薬剤

Also Published As

Publication number Publication date
DE3476785D1 (en) 1989-03-30
EP0151593B1 (en) 1989-02-22
US4604285A (en) 1986-08-05
WO1985000521A1 (en) 1985-02-14
EP0151593A1 (en) 1985-08-21
GB8319538D0 (en) 1983-08-24
JPH0567278B2 (enExample) 1993-09-24

Similar Documents

Publication Publication Date Title
JPS60501859A (ja) 酵素誘導体
Landerman et al. Hereditary angioneurotic edema: II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein
HU182458B (en) Process for preparing enzyme derivatives with in vivo fibrinolytic activity
JPS60252422A (ja) ハイブリツド蛋白質、その製法及びそれを含む医薬組成物
US4471053A (en) Process for producing a vasal fibrinolytic active principle and the enzymatic product so prepared
RU2138275C1 (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
AU659807B2 (en) Platelet adhesion inhibitor
US5547850A (en) Process for determining hirudin and synthetic thrombin inhibitors
Silberman et al. Effects of ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity
US3228841A (en) Diagnostic reagent composition for determining blood coagulation factors and method of use
CA1202895A (en) Thrombolytic composition
JPS59110625A (ja) プラスミノ−ゲン活性化因子、その製造法およびその製造用生産物
Wolf Modification of the fibrin agar plate for measurements of the components of the fibrinolytic system
US3509024A (en) Aspergillopeptidase for use in therapy and a process for the preparation thereof
KR0135980B1 (ko) 플라스미노겐 액티베이터 및 혈전용해제
Aziz et al. Congenital deficiency of fibrin-stabilizing factor (factor XIII): a report of four cases (two families) and family members
Ronwin The significance of human blood trypsin; direct determination of thrombin and plasmin in human plasma
JPH0391498A (ja) 血液試料中の凝固因子の回収を向上させるための安定化剤
US20230295597A1 (en) A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof
JP2632073B2 (ja) アルギニン特異的カルボキシペプチダーゼ及び臨床検査法
WO2015172215A1 (pt) Selante de fibrina para uso tópico, método de formação do mesmo e seu uso
KR100361805B1 (ko) 룸브로키나제의 액상제재화 방법 및 그 방법에 의한액상혈전용해제
JPWO1987000050A1 (ja) 血液凝固制御作用を有する新たな生理活性物質
JPS6055488B2 (ja) 線溶活性を有する治療用組成物、これを主成分とする治療剤、及びその製造方法
FODSTAD B. DAHLERUP

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term